Teradyne price target raised to $165 from $130 at UBS

UBS raised the firm’s price target on Teradyne (TER) to $165 from $130 and keeps a Buy rating on the shares. UBS sees upside to Q4 guidance, but the stock reaction may be dependent on how Teradyne messages a tough memory test comp between Q4 and 1Q26, the analyst tells investors in a research note. UBS does not anticipate a major shift in tone from Teradyne, as management is likely to reiterate optimism around several large, emerging opportunities.